参麦注射液联合TP方案同步放疗治疗中晚期宫颈癌的临床观察

目的:观察参麦注射液联合多西紫杉醇+顺铂(TP)方案同步三维适形放疗治疗中晚期宫颈癌的临床疗效。方法:将65例中晚期宫颈癌患者随机分为治疗组和对照组,治疗组33例,接受三维适形放疗同步TP方案化疗,治疗过程中同时给予参麦注射液治疗;对照组32例,仅接受三维适形放疗同步TP方案化疗。观察2组患者的T细胞亚群变化、生存质量、近期疗效及毒副反应。结果:治疗组CD3+、CD4+、CD16+CD56+和CD4+/CD8+比值等与对照组比较显著上升,CD8+效应细胞比例下降,差异均有统计学意义(P<0.05)。治疗组有60.6%的患者生存质量改善,明显高于对照组的31.3%(P<0.05)。治疗组的有效率为72.7%,明显高于对照组的43.8%(P<0.05)。治疗组的1年生存率为66.7%,明显高于对照组的37.5%(P<0.05)。治疗组白细胞下降、贫血、血小板下降的发生率均低于对照组,2组比较差异有统计学意义(P<0.05)。结论:参麦注射液联合TP方案同步放疗治疗中晚期宫颈癌安全、有效,对提高机体免疫力、改善生存质量、提高近期疗效及保护骨髓功能具有重要作用。

Clinical Observation of Shenmai Injection Combined with TP Regimen Concurrent Radiotherapy in the Treatment of Moderate and Advanced Cervical Cancer

OBJECTIVE:To observe the clinical efficacy of three-dimensional conformal radiotherapy of Shenmai injection combined with TP regimen in treatment of moderate and advanced cervical cancer.METHODS:A total of 65 patients with moderate and advanced cervical cancer were randomly divided into treatment group and control group.In treatment group,33 patients received simultaneous three-dimensional conformal radiotherapy combined with TP(docetaxel+cisplatin) chemotherapy and given Shenmai injection at the same time.In control group,32 patients only received concurrent radiotherapy.The T-cell subsets changes,changes in quality of life,short-term efficacy and toxicity were observed in 2 groups.RESULTS:Compared with control group,the percentages of CD3+,CD4+,CD16+CD56+ and CD4+/CD8+ in treatment group increased significantly and the percentages of CD8+ effect cells decreased significantly,there was statistical significance(P<0.05).Quality of life was improved in 60.6% patients of treatment group,which was significantly higher than 31.3% in control group(P<0.05).The response rate(RR) of treatment group were 72.7%,which was higher than 43.8% in control group(P<0.05).The 1-year survival rate of treatment group was 66.7%,which was significantly higher than 37.5% of control group(P<0.05).The incidence rates of leukopenia,anemia,thrombocytopenia in treatment group were lower than in control group,there were significantly different(P<0.05).CONCLUSIONS:Shenmai injection combined with TP regimen concurrent radiotherapy in moderate and advanced cervical cancer is safe and effective and it play an important role in improving immune function,quality of life,short-term efficacy and protecting bone marrow function.